Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By


POM to P switch for Sudafed Plus Blocked Nose nasal spray

Sudafed Plus Blocked Nose 1mg/50mg/ml nasal spray will become available to buy in pharmacies without a prescription.

The Medicines and Healthcare products Regulatory Agency (MHRA) has decided that the nasal spray is “sufficiently safe to be sold as a pharmacy (P) medicine”, it announced today (August 3).

It follows an application by its marketing authorisation holder, McNeil Products Limited, to reclassify the prescription-only medicine (POM) to a P medicine.

The nasal spray contains xylometazoline hydrochloride 1mg/ml (0.1% w/v) and dexpathenol 50mg/ml (5% w/v).

The MHRA came to the decision having reviewed a raft of evidence about the drug and assessing any potential of risk to patient safety.

Pharmacists will now be able to dispense the nasal spray solution without prescription to adults and children aged 12 years and older suffering from nasal congestion.

C+D has asked the MHRA when the reclassification will come into effect.


Related Content


Yeovil, Winchester & Dorchester
£50-55,000 per annum

Apply Now
Latest News & Analysis
See All



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts